Personalized Cancer Therapies via OPCML Fragmentation and AI-driven Targeting

A next-generation cancer treatment system that leverages advanced genomics, machine learning, and targeted nanotherapy to provide personalized, adaptive, and effective treatments for various cancer types, revolutionizing the field of cancer prognosis, theragnosis, and research.

The original patent relates to the role of OPCML in cancer prognosis, theragnosis, treatment, and research. However, it is limited to administering a specific OPCML fragment for tumor suppressor protein therapy. The present inventive concept addresses the limitations of the original patent by envisioning a more ambitious and forward-thinking approach, integrating cutting-edge technologies to provide a paradigm shift in cancer treatment.

The inventive concept comprises a system for personalized cancer treatment, which utilizes a database of genomic profiles to identify specific OPCML variants associated with a patient's cancer. A therapeutic module then administers a customized OPCML fragment based on the identified variant. Additionally, the system incorporates a machine learning model to predict cancer relapse probability, guiding personalized treatment strategies. The composition for targeted cancer therapy comprises nanoparticles encapsulating OPCML fragments, engineered to selectively target cancer stem cells and induce apoptosis. A device for real-time monitoring of OPCML expression levels provides feedback for adjusting treatment regimens. Furthermore, the inventive concept includes a method for generating OPCML-based cancer vaccines through in vitro expansion of dendritic cells using OPCML peptides.

The new claims introduce novel and non-obvious elements, including the integration of genomics, machine learning, and targeted nanotherapy, which enable personalized, adaptive, and effective cancer treatments. The inventive concept's fusion of advanced technologies and biomarkers provides a significant departure from the original patent, making it more ambitious and forward-thinking.

Alternative embodiments may include the use of different machine learning models, varying nanoparticle designs, or incorporating additional biomarkers. Variations may also involve adapting the system for different cancer types or utilizing different OPCML fragments.

The inventive concept has immense commercial potential in the cancer treatment and research markets, with potential applications in personalized medicine, targeted therapies, and cancer vaccine development. The target industries include pharmaceutical companies, biotech firms, and healthcare providers.